Drug Trial Radar · NCT03658772
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Sep 20, 2018
Primary completion
Mar 7, 2023
Study completion Mar 7, 2023
Sponsor
- Lead sponsor
- Arrys TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted in adult participants diagnosed with any form of an advanced or progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which contained fluorouracil) is no longer effective or is intolerable. This is a phase 1b, multi-center, open label study designed to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be assessed.
Conditions
- Microsatellite Stable Colorectal Cancer
Interventions
grapiprantDrug
Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
grapiprant and pembrolizumabDrug
Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of grapiprant alone and in combination with pembrolizumabTime frame: Up to 90 days after the end of treatment (average of 7 months)
- Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumabTime frame: Through Cycle 1 (21 days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center - Scottsdale
Phoenix, Arizona
University of Colorado Denver-Anschutz Medical Campus
Aurora, Colorado
Sarah Cannon Research Institute, LLC (SCRI)
Nashville, Tennessee
New Experimental Therapeutics of San Antonio-NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.